CD8A and myeloid sarcoma: EBV-targeted immunotherapies are being explored to reverse exhausted EBV-targeted T cell responses, particularly the CD8+ cytotoxic T lymphocyte (CTL) response, which is thought to lead to poor virus control and increased MS disease activity54,98.